United Therapeutics (BSP:U2TH34) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:U2TH34 United Therapeutics Corp BSP:U2TH34
65 GF Score
Price R$133.00
GF Value R$97.31
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is United Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BSP:U2TH34
65GF Score
United Therapeutics Corp BSP:U2TH34
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of R$133.00 is trading 36.7% above its estimated GF Value™ of R$97.31. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for BSP:U2TH34:

  • Short Ratio:
  • GF Value™: R$97.31 vs. price of R$133.00 (36.7% above fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTHR:USAUTH:Germany
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
65GF Score

Get the complete analysis for BSP:U2TH34

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$133.00
Price
R$97.31
GF Value